Supernus Pharmaceuticals Inc. | Mutual Funds
Mutual Funds that own Supernus Pharmaceuticals Inc.
iShares Core S&P Small Cap ETF
2,861,653
5.53%
810
0.27%
09/06/2018
Vanguard Total Stock Market Index Fund
1,239,827
2.39%
14,106
0.01%
07/31/2018
Vanguard Small Cap Index Fund
1,239,172
2.39%
17,634
0.06%
07/31/2018
iShares Russell 2000 ETF
1,032,291
1.99%
-552
0.09%
09/06/2018
iShares S&P Small Cap 600 Growth ETF
888,552
1.72%
1,275
0.54%
09/06/2018
Vanguard Small Cap Growth Index Fund
706,844
1.37%
10,372
0.12%
07/31/2018
Vanguard Extended Market Index Fund
685,331
1.32%
7,300
0.04%
07/31/2018
iShares Nasdaq Biotechnology ETF
598,217
1.15%
-7,812
0.27%
09/06/2018
PowerShares S&P Small Cap Health Care Portfolio
593,872
1.14%
37,763
2.1%
09/05/2018
Government Pension Fund - Global (The)
586,591
1.12%
586,591
0%
12/31/2017
| Address |
1550 East Gude Drive
Rockville Maryland 20850
United States
|
|
Employees
|
- |
| Website |
http://www.supernus.com |
| Updated |
07/08/2019 |
| Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. |
